Comparison of AS03 and Alum on immune responses elicited by A/H3N2 split influenza vaccine in young, mature and aged BALB/c mice

Vaccine

Volumn 34, Issue 12, 2016, Pages 1444-1451

  Yam, Karen K ^a   Gupta, Jyotsana ^a   Allen, Elizabeth K ^a   Burt, Kayla R ^a   Beaulieu, Édith ^b   Mallett, Corey P ^b   Burt, David S ^b   Ward, Brian J ^a  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b GLAXOSMITHKLINE   (Canada)

Author keywords

Adjuvant; Aged mice; Alhydrogel; Alum; AS03; Avidity; Chemokine; Cytokine; H3N2 virus; Hemagglutination inhibition; Immunosenescence; Influenza virus; Microneutralization; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; AS 03; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG; ALPHA TOCOPHEROL; ALUMINUM SULFATE; ASO3B ADJUVANT; CYTOKINE; DRUG COMBINATION; POLYSORBATE; SQUALENE; VIRUS ANTIBODY;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; FEMALE; HEMAGGLUTINATION INHIBITION; HUMORAL IMMUNITY; INFLUENZA A VIRUS (H3N2); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VIRUS ENTRY; YOUNG ADULT; AGE; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG COMBINATION; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; ORTHOMYXOVIRIDAE INFECTIONS; SERODIAGNOSIS; SPLEEN;

ADJUVANTS, IMMUNOLOGIC; AGE FACTORS; ALPHA-TOCOPHEROL; ALUM COMPOUNDS; ANIMALS; ANTIBODIES, VIRAL; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DRUG COMBINATIONS; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS; POLYSORBATES; SPLEEN; SQUALENE;

EID: 84959096871     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.02.012     Document Type: Article

References (40)

1. Matias G., Taylor R., Haguinet F., Schuck-Paim C., Lustig R., Shinde V. Estimates of mortality attributable to influenza and RSV in the United States during 1997-2009 by influenza type or subtype, age, cause of death, and risk status. Influenza Other Respir Viruses 2014, 8(Sep (5)):507-515.
2. Huber V.C. Influenza vaccines: from whole virus preparations to recombinant protein technology. Expert Rev Vaccines 2014, 13(1):31-42.
3. De Villiers P.J., Steele A.D., Hiemstra L.A., et al. Efficacy and safety of a live attenuated influenza vaccine in adults 60 years of age and older. Vaccine 2009, 28(Dec (1)):228-234.
4. Forrest B.D., Steele A.D., Hiemstra L., Rappaport R., Ambrose C.S., Gruber W.C. A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older. Vaccine 2011, 29(May (20)):3633-3639.
5. McElhaney J.E., Coler R.N., Baldwin S.L. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev Vaccines 2013, 12(7):759-766.
6. Podda A. The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 2001, 19(Mar (17-19)):2673-2680.
7. Banzhoff A., Nacci P., Podda A. A new MF59-adjuvanted influenza vaccine enhances the immune response in the elderly with chronic diseases: results from an immunogenicity meta-analysis. Gerontology 2003, 49(May (3)):177-184.
8. Tetsutani K., Ishii K.J. Adjuvants in influenza vaccines. Vaccine 2012, 30(Dec (52)):7658-7661.
9. Keitel W.A., Atmar R.L., Cate T.R., et al. Safety of high doses of influenza vaccine and effect on antibody responses in elderly persons. Arch Intern Med 2006, 166(May (10)):1121-1127.
10. de Bruijn I.A., Nauta J., Gerez L., Palache A.M. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects). Vaccine 2006, 24(Nov (44-46)):6629-6631.
11. Mannino S., Villa M., Apolone G., et al. Effectiveness of adjuvanted influenza vaccination in elderly subjects in northern Italy. Am J Epidemiol 2012, 176(Sep (6)):527-533.
12. DiazGranados C.A., Dunning A.J., Jordanov E., Landolfi V., Denis M., Talbot H.K. High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 2013, 31(Jan (6)):861-866.
13. DiazGranados C.A., Dunning A.J., Kimmel M., et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014, 371(Aug (7)):635-645.
14. Morel S., Didierlaurent A., Bourguignon P., et al. Adjuvant System AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29(Mar (13)):2461-2473.
15. Segal L., Wouters S., Morelle D., et al. Non-clinical safety and biodistribution of AS03-adjuvanted inactivated pandemic influenza vaccines. J Appl Toxicol 2015, 35(Dec (12)):1564-1576.
16. Garcon N., Vaughn D.W., Didierlaurent A.M. Development and evaluation of AS03, an adjuvant system containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines 2012, 11(3):349-366.
17. Fox C.B., Haensler J. An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants. Expert Rev Vaccines 2013, 12(7):747-758.
18. Yang W.H., Dionne M., Kyle M., et al. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial. Vaccine 2013, 31(Sep (40)):4389-4397.
19. Couch R.B., Bayas J.M., Caso C., et al. Superior antigen-specific CD4+ T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older. BMC Infect Dis 2014, 14:425.
20. Leroux-Roels G. Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data. Expert Opin Biol Ther 2009, 9(8):1057-1071.
21. Yam K.K., Gupta J., Brewer A., Scheifele D.W., Halperin S., Ward B.J. Unusual Patterns of IgG avidity in some young children following two doses of the adjuvanted Pandemic H1N1 (2009) Influenza Virus Vaccine. Clin Vaccine Immunol 2013, 20(4):459-467.
22. Scheifele D.W., Ward B.J., Dionne M., et al. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J 2011, 30(5):402-407.
23. Yam K.K., Gupta J., Winter K., et al. AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB/c Mice. Front Immunol 2015, 6:207.
24. World Health Organization Recommended Composition of Influenza Virus Vaccines for Use in the 2009-2010 Influenza Season February, 2009, World Health Organization, Available from 〈http://www.who.int/entity/influenza/vaccines/200902_recommendation.pdf〉.
25. Feng J., Gulati U., Zhang X., et al. Antibody quantity versus quality after influenza vaccination. Vaccine 2009, 27(Oct (45)):6358-6362.
26. Lefebvre J.S., Haynes L. Vaccine strategies to enhance immune responses in the aged. Curr Opin Immunol 2013, 25(Aug (4)):523-528.
27. O'Hagan D.T., Ott G.S., Nest G.V., Rappuoli R., Giudice G.D. The history of MF59((R)) adjuvant: a phoenix that arose from the ashes. Expert Rev Vaccines 2013, 12(1):13-30.
28. Rumke H.C., Richardus J.H., Rombo L., et al. Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis 2013, 13:348.
29. Martin J.T. Development of an adjuvant to enhance the immune response to influenza vaccine in the elderly. Biologicals 1997, 25(Jun (2)):209-213.
30. Wack A., Baudner B.C., Hilbert A.K., et al. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008, 26(Jan (4)):552-561.
31. Flurkey K., Currer J., Harrison D. The mouse in aging research. The mouse in biomedical research 2007, 637-672. American College Laboratory Animal Medicine (Elsevier), Burlington, MA, (Fig. 20-3). 2nd ed. J. Fox, S. Barthhold, M. Davisson, C. Newcomer, F. Quimby, A. Smith (Eds.).
32. Baz M., Samant M., Zekki H., et al. Effects of different adjuvants in the context of intramuscular and intranasal routes on humoral and cellular immune responses induced by detergent-split A/H3N2 influenza vaccines in mice. Clin Vaccine Immunol 2012, 19(2):209-218.
33. Wen Z., Ye L., Gao Y., et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge. Antiviral Res 2009, 84(Dec (3)):215-224.
34. Bungener L., Geeraedts F., Ter V.W., Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008, 26(May (19)):2350-2359.
35. Oleszycka E., Lavelle E.C. Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 2014, 28(Jun):1-5.
36. Landry N., Pillet S., Favre D., et al. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens. Clin Immunol 2014, 154(Oct (2)):164-177.
37. Middleton D., Rockman S., Pearse M., et al. Evaluation of vaccines for H5N1 influenza virus in ferrets reveals the potential for protective single-shot immunization. J Virol 2009, 83(Aug (15)):7770-7778.
38. Layton R.C., Gigliotti A., Armijo P., et al. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret. PLoS ONE 2011, 6(6):e20641.
39. Schneider-Ohrum K., Giles B.M., Weirback H.K., Williams B.L., DeAlmeida D.R., Ross T.M. Adjuvants that stimulate TLR3 or NLPR3 pathways enhance the efficiency of influenza virus-like particle vaccines in aged mice. Vaccine 2011, 29(Nov (48)):9081-9092.
40. Magnusson S.E., Reimer J.M., Karlsson K.H., Lilja L., Bengtsson K.L., Stertman L. Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 2013, 31(Mar (13)):1725-1733.